Lipid-altering agents: the future

Author: A.S. Wierzbicki

Source: International Journal of Clinical Practice, Volume 58, Number 11, November 2004 , pp. 1063-1072(10)

Buy & download fulltext article:

Price: $48.00 plus tax (Refund Policy)

Abstract:

Summary

Lipid-lowering is established as proven intervention to reduce atherosclerosis and its complications. This article summarises novel developments in the lipid-altering therapies under development. It also discusses other therapeutic targets, such as squalene synthase, microsomal transfer protein, acyl-cholesterol acyl transferase, cholesterol ester transfer protein, peroxosimal proliferator-activating receptors and lipoprotein (a), for which compounds have been developed and have at least reached trials in animal models. Lipid-altering drugs are likely to prove a fast-developing area for novel treatments, as possible synergies exist between new and established compounds for the treatment of atherosclerosis.

Keywords: Cholesterol; risk factor; HDL; LDL; therapy; treatment

Document Type: Research article

DOI: http://dx.doi.org/10.1111/j.1742-1241.2004.00087.x

Affiliations: 1: St. Thomas' Hospital Campus, Lambeth Palace Road, London, UK

Publication date: 2004-11-01